BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will ...

Core Insights - CorMedix (CRMD) acquired Melinta Therapeutics for $300 million in August 2025, diversifying its revenue base and reducing reliance on its primary product, DefenCath [1][12] - The acquisition added seven approved products to CRMD's portfolio, contributing $12.8 million to its revenue in Q3 2025 [2][12] - DefenCath, approved by the FDA in late 2023, generated $167.6 million in net sales during the first nine months of 2025 [3] Revenue and Growth Opportunities - The Melinta acquisition is expected to create near-term growth opportunities, particularly through Rezzayo, which targets a market exceeding $2 billion for antifungal prophylaxis [4] - CRMD raised its full-year 2025 pro forma net revenue guidance to $390-$410 million, up from a previous estimate of at least $375 million, reflecting strong momentum from DefenCath and early contributions from Melinta [5] Competitive Landscape - Despite strong adoption of DefenCath, competition from major players like Pfizer, Amphastar Pharmaceuticals, and others poses a risk to CRMD's market position [6][7] - These competitors have stronger pipelines and greater resources, which could challenge CorMedix's growth outlook [8] - If Pfizer or Amphastar expands into catheter-related infection prevention, CRMD may face significant competitive pressure [10] Stock Performance and Valuation - CRMD shares have decreased by 2.5% over the past six months, underperforming the industry, which has rallied by 26.8% [13] - The stock is trading at a discount to the industry, with a price/book ratio of 2.55 compared to the industry average of 3.68 [14] - Earnings estimates for 2025 have improved from $1.85 to $2.87 per share, and for 2026 from $2.49 to $2.88 [15]

CorMedix signage outside a biopharmaceutical laboratory, signifying the company's promising clinical-stage results. Key Points CorMedix is best known for its catheter lock solutions, products designed to reduce the risk of infection for dialysis patients. DefenCath is one of the company's leading products, having recently achieved promising results in both reducing catheter-related infections and related hospitalizations. The company's other leading candidate, REZZAYO, should see Phase III trial data i ...

BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care’s (USRC) use of DefenCath in adult hemodialysis patients with central venous catheters. CorMedix and USRC commenced the real-world evidence stu ...

Key Takeaways CRMD is ramping DefenCath sales after the 2024 launch, while Puma Biotechnology leans on Nerlynx.CRMD posted $167.6M DefenCath sales in the first nine months of 2025, with patent protection to 2033.PBYI lifted 2025 Nerlynx sales guidance, but reliance on one product and competition persist.CorMedix (CRMD) and Puma Biotechnology (PBYI) are small-cap biotech companies focused on the successful commercialization of their core products as they work to establish leadership within their respective d ...

Key Takeaways CRMD's DefenCath sales hit $167.6M in the first nine months of 2025, driving the stock's YTD surge.Higher outpatient utilization and planned label expansion are expected to support DefenCath growth.The $300M Melinta deal adds seven therapies and diversified opportunities, including Rezzayo.Shares of CorMedix (CRMD) have witnessed a strong surge so far this year, primarily driven by the continued strong uptake of the company’s lead marketed therapy, DefenCath (Taurolidine + Heparin). The stock ...

Key Takeaways CRMD's DefenCath is an FDA-approved catheter lock solution reducing CRBSIs in chronic hemodialysis patients.DefenCath posted $167.6M in nine-month sales in 2025, supported by market exclusivity through 2033.Melinta's acquisition added seven products and boosted CRMD's revenue outlook to $390-$410M for 2025.CorMedix’s (CRMD) lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver.The FDA approved DefenCath in late 2023 as the first and only antimicrob ...

Core Insights - CorMedix Inc. is recognized as a promising investment opportunity, with a reaffirmed Buy rating due to strong revenue from DefenCath and growth catalysts like Rezzayo and TPN Phase 3 data expected in 2026 [1][2] - The company reported robust third-quarter results, achieving $104.3 million in net revenue and $130.8 million in pro forma net revenue, primarily driven by increased utilization of DefenCath among outpatient dialysis customers [2][3] - CorMedix returned to profitability with a net income of $108.6 million, or $1.26 per share, a significant improvement from a net loss of $2.8 million, or $0.05 per share, in the same quarter last year [3] - The company has raised its full-year 2025 pro forma net revenue forecast to between $390 million and $410 million, with net revenue expectations of $115 million to $135 million, bolstered by anticipated synergies of $30 million from the Melinta Therapeutics acquisition [4] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for infectious and inflammatory diseases, with its lead product being DefenCath, an antimicrobial catheter lock solution aimed at preventing catheter-related bloodstream infections in hemodialysis patients [5]

Core Insights - CorMedix Inc. (NASDAQ:CRMD) is recognized as a fast-growing small-cap stock, with analysts recommending it as a buy following a strong earnings report for fiscal Q3 2025 [1][2] - The company reported a significant revenue increase of 810.21% year-over-year, reaching $104.28 million, which exceeded estimates by $18.25 million [2] - Earnings per share (EPS) for the quarter was $1.26, surpassing consensus estimates by $0.63 [2] Financial Performance - The revenue growth was primarily driven by higher utilization of DefenCath among outpatient dialysis customers, contributing $88.8 million to net revenue [2] - CorMedix raised its full-year pro forma net revenue guidance to a range of $390 to $410 million and fourth-quarter guidance to $115 to $135 million [3] Strategic Developments - The recent acquisition of Melinta has diversified CorMedix's business and contributed to its robust financial results [4] - The company has a promising pipeline with significant growth catalysts, including anticipated results from the Rezzayo study and TPN Phase 3 data for DefenCath [4] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products aimed at preventing and treating life-threatening infectious and inflammatory diseases [5]

Core Insights - CorMedix Inc. reported third-quarter earnings of $1.26 per share, significantly exceeding the consensus estimate of 63 cents [1] - Sales reached $104.27 million, a substantial increase from $11.5 million a year ago, surpassing the consensus of $86.02 million [1] - The net revenue of $104.3 million and pro forma net revenue of $130.8 million were primarily driven by higher-than-expected utilization of DefenCath by outpatient dialysis customers [1] Financial Performance - The company recognized a net income of $108.6 million and adjusted EBITDA of $71.9 million [2] - Cash, cash equivalents, and short-term investments totaled $55.7 million [2] Guidance and Projections - CorMedix raised its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, compared to the consensus of $283.69 million [2] - Fourth quarter net revenue guidance was increased to $115 to $135 million, compared to the Wall Street estimate of $118.85 million [2] - The guidance for fully synergized pro forma adjusted EBITDA for 2025 was increased to a range of $220 to $240 million [3] Strategic Developments - The acquisition of Melinta Therapeutics was completed in August, with integration efforts proceeding more quickly than projected [3] - CorMedix estimates a synergy capture of approximately $30 million of the total estimated $35 to $45 million on an annual run-rate basis before the end of 2025 [3] Market Reaction - CRMD stock increased by 12.06% to $12.54 following the earnings report [4]